Prior Training Increases Internists’ Knowledge of PrEP for HIV
IM residents with training report more frequent prescribing, higher comfort level in educating patients
Antiretrovirals
Generic Version of Truvada Available in the United States by September 2020
A generic version of the HIV PrEP drug Truvada will be available in the United States by fall 2020.
Increased Incidence of STIs in Gay/Bisexual Men Who Received HIV PrEP
An increased incidence of sexually transmitted infections was associated with the receipt of HIV pre-exposure prophylaxis in gay and bisexual men
Successful Dolutegravir-Based ART for Patients With TB/HIV Co-Infection
Dolutegravir in combination with 2 NRTIs is well tolerated and may produce rapid virologic and immunologic responses in patients with TB and HIV.
ART Interruption With Close Monitoring, Strict Restart Guidelines Safe in HIV Cure Trials
Analytical treatment interruption caused neither expansion of HIV reservoirs nor immunologic abnormalities after reinitiation of antiretroviral therapy.
Dolutegravir-Based Strategies Offer Benefits for Women With HIV
Dolutegravir-based antiretroviral therapy may lead to both fewer deaths in women and fewer overall HIV transmissions.
Benefit of Early ART Initiation in HIV-Infected Children and Adolescents
Early initiation of antiretroviral therapy and improved nutrition in children with HIV were positively associated with lung function.
Dual Therapy With Rilpivirine and Boosted Darunavir Is Effective in PLWHIV
Rilpivirine plus boosted-darunavir dual therapy may be effective and safe in patients with advanced HIV.
Predictors of Doravirine Resistance After Exposure to NNRTIs
Doravirine resistance is uncommon in people with HIV who have been treated with non-nucleoside reverse transcriptase inhibitors.
First Two-Drug Regimen Approved for HIV-1 Treatment
The FDA has announced the approval of Dovato for adults with HIV-1 who have not been previously treated with antiretroviral medication.
Next post in HIV/AIDS
